Zealand Pharma A/S/€ZEAL
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.
Ticker
€ZEAL
Sector
Primary listing
XGAT
Employees
440
Headquarters
Søborg, Denmark
Website
ZEAL Metrics
BasicAdvanced
€4.6B
5.42
€12.27
0.54
-
Price and volume
Market cap
€4.6B
Beta
0.54
52-week high
€108.46
52-week low
€41.44
Average daily volume
1.8K
Financial strength
Current ratio
14.103
Quick ratio
14.103
Long term debt to equity
2.532
Total debt to equity
2.681
Interest coverage (TTM)
233.70%
Profitability
EBITDA (TTM)
948.03
Gross margin (TTM)
99.99%
Net profit margin (TTM)
71.47%
Operating margin (TTM)
77.23%
Effective tax rate (TTM)
8.05%
Revenue per employee (TTM)
€2,786,040
Management effectiveness
Return on assets (TTM)
33.44%
Return on equity (TTM)
54.42%
Valuation
Price to earnings (TTM)
5.421
Price to revenue (TTM)
3.83
Price to book
2.28
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
4.757
Free cash flow yield (TTM)
21.02%
Free cash flow per share (TTM)
13.981
Growth
Revenue change (TTM)
11,809.72%
Earnings per share change (TTM)
-651.45%
3-year revenue growth (CAGR)
360.92%
10-year revenue growth (CAGR)
79.16%
3-year earnings per share growth (CAGR)
52.64%
10-year earnings per share growth (CAGR)
23.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zealand Pharma A/S stock?
Zealand Pharma A/S (ZEAL) has a market cap of €4.6B as of December 15, 2025.
What is the P/E ratio for Zealand Pharma A/S stock?
The price to earnings (P/E) ratio for Zealand Pharma A/S (ZEAL) stock is 5.42 as of December 15, 2025.
Does Zealand Pharma A/S stock pay dividends?
No, Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders as of December 15, 2025.
When is the next Zealand Pharma A/S dividend payment date?
Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zealand Pharma A/S?
Zealand Pharma A/S (ZEAL) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.